[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gbs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gbs":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":5},"100429358","immunoadsorption-versus-plasma-exchange-for-treatment-of-guillain-barr-syndrome-gbs-100429358",false,"NCT04871035","Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)","IPET-GBS","Inclusion Criteria:\n\n* Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008)\n* age 18 years or above\n\nExclusion Criteria:\n\n* Clinical or laboratory (C-reactive protein 20 mg\u002Fl or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection\n* Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment\n* Other contraindications against immunoadsorption or plasma exchange","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","OBSERVATIONAL","This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.",[24],"GBS","RECRUITING","2026-04-30",{"date":28,"type":29},"2026-05-01","ACTUAL",{"date":31,"type":29},"2021-04-28",{"date":33,"type":20},"2027-09-01",{"name":35,"class":36},"University of Ulm","OTHER"]